Perspective Therapeutics (NYSE:CATX) Rating Lowered to “Neutral” at Bank of America

Perspective Therapeutics (NYSE:CATX) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a report released on Monday, Marketbeat.com reports. They presently have a $5.00 price target on the stock, down from their prior price target of $24.00. Bank of America‘s target price would suggest a potential upside of 14.42% from the stock’s current price.

Several other research firms also recently issued reports on CATX. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Oppenheimer decreased their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Wedbush restated an “outperform” rating and issued a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $4.37 on Monday. The company has a fifty day simple moving average of $11.15. Perspective Therapeutics has a 12 month low of $2.28 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million for the quarter. Analysts predict that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor purchased 14,500 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the acquisition, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CATX. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the second quarter worth about $117,000. Point72 DIFC Ltd purchased a new position in Perspective Therapeutics during the second quarter worth about $118,000. Finally, Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $137,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.